Drug intelligence / Profile preview

BDR-662

Development stage: Preclinical
Lead developer: MDimune
Modality: miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

BDR-662 is an investigational RNA interference (RNAi) drug candidate developed by MDimune. It utilizes exosome-based delivery of microRNA (miRNA) for therapeutic purposes. The primary mechanism of action is RNA interference, which involves the silencing of specific gene expression at the mRNA level. BDR-662 is being explored for indications in eye diseases and remains in preclinical development as of March 2025[9].

Beyond the preview

Go deeper on BDR-662.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDR-662.

Explore the full profile